



(12) Translation of
European patent specification

(11) NO/EP 3999042 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 31/05 (2006.01)

A61K 31/352 (2006.01)

A61K 31/47 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2023.11.20
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.10.11
(86)	European Application Nr.	20751200.5
(86)	European Filing Date	2020.07.17
(87)	The European Application's Publication Date	2022.05.25
(30)	Priority	2019.07.19, GB, 201910389
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	GW Research Limited, Sovereign House Vision Park Chivers Way Histon, Cambridge, Cambridgeshire CB24 9BZ, Storbritannia
(72)	Inventor	SILCOCK, Alan, GW Pharma Limited Sovereign House Vision Park Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ, Storbritannia WHALLEY, Benjamin, GW Pharma Limited Sovereign House Vision Park Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ, Storbritannia GRAY, Royston, GW Pharma Limited Sovereign House Vision Park Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ, Storbritannia STRAKER, Hannah, GW Pharma Limited Sovereign House Vision Park Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ, Storbritannia TSE, Karen, GW Pharma Limited Sovereign House Vision Park Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ, Storbritannia COBB, Alexander, Department of Chemistry King's College London 7 Trinity Street, London SE1 1DB, Storbritannia BRYANT, Laura, 9 Leighcroft Gardens, Leigh-on-sea Essex SS9 4NP, Storbritannia
(74)	Agent or Attorney	Nordic Patent Service A/S, Bredgade 30, 1260 KØBENHAVN K, Danmark

(54) Title **CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND
METHODS OF PREPARATION THEREOF**


(56) References
Cited: EP-A1- 3 061 450
 WO-A2-01/95899
 WO-A1-2014/062965

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Forbindelse av den generelle formelen I eller et salt derav


Formel I



- 5 der X er enten CH₂; O; NBoc; NFMoc; NZ; NTs; NAc; NC(O)iPr; NBz eller NH og Y er enten H eller OH.

2. Forbindelse av den generelle formelen II eller et salt derav

Formel II



- 10 der X er enten CH₂; O; NBoc; NFMoc; NZ; NTs; NAc; NC(O)iPr; NBz eller NH og Y er enten H eller OH.

3. Farmasøytisk sammensetning omfattende en forbindelse ifølge krav 1 eller krav 2.

- 15 4. Farmasøytisk sammensetning ifølge krav 3, hvori den farmasøytiske sammensetningen velges fra en tablett, en kapsel, et granulat, et pulver for inhalering, et dryss, en oral oppløsning og en suspensjon.


5. Farmasøytisk sammensetning ifølge krav 3 eller krav 4, hvori sammensetningen i tillegg omfatter én eller flere av: en eksipiens valgt blant en bærer, en olje, et desintegreringsmiddel, et smøremiddel, en stabilisator, et smaksmiddel, en antioksidant, et fortynningsmiddel og en annen farmasøytisk effektiv forbindelse.

5

6. Forbindelse ifølge krav 1 eller krav 2 for anvendelse som et medikament.











7. Forbindelse ifølge krav 1 eller krav 2 for anvendelse i behandlingen av epilepsi.

10 8. Prosess for fremstillingen av en forbindelse av generell formel I ifølge krav 1, eller generell formel II ifølge krav 2, omfattende reagering av en resorcinolenhet med struktur 1a-e eller 1g-j via en Friedel-Crafts 1,4-tilsetning for å fremstille forbindelser av strukturene 2a-e eller 2g-j, eller 3a-e eller 3g-j:



15 $R_1 = H$; $X = CH_2$; O; NBoc; NFmoc; NZ; NTs; NAc; NC(O)iPr; eller NBz etterfulgt av påfølgende trinn for å fremstille forbindelsene av generell formel I eller II via mellomprodukter.

9. Mellomprodukt dannet i prosessen med fremstillingen av en forbindelse av generell formel I eller formel II, hvori mellomproduktet velges fra:

 2a-e og 2g-j	 3a-e og 3g-j
 4a-e og 4g-j	 5a-e og 5g-j
 6a-e og 6g-j	 7a-e og 7g-j
 9a-e og 9g-j	 10a-e og 10g-j
 15a-e og 15g-j	 16a-e og 16g-j

der $R_1 = H$, og $X = CH_2$; O; NBoc; NFmoc; NZ; NTs; NAc; NC(O)iPr; eller NBz.